Meta-Analysis of Immunohistochemical Markers for Differentiating Benign and Malignant Mesenchymal Tumors
International Journal of Current Pharmaceutical Review and Research · 30.01.2026 · 18 (01)
DOI: 10.25258/ijcpr.18.1.233 ↗Kurz gefasst
Metaanalyse in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 30.01.2026. Verfasst von Vivek Tripathi und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Mesenchymal tumors include a diverse range of benign and malignant neoplasms exhibiting overlapping histomorphological characteristics. Precise differentiation between benign and malignant mesenchymal tumors is essential for prognosis and management, although frequently presents diagnostic difficulties. Immunohistochemistry (IHC) is crucial for clarifying these uncertainties; yet, the diagnostic value of specific markers differs among research.
Objective
To conduct a thorough review and meta-analysis of the diagnostic efficacy of frequently utilized immunohistochemistry markers in distinguishing benign from malignant mesenchymal tumors.
Methods
A comprehensive literature search was performed on PubMed, Scopus, Web of Science, and Google Scholar for papers published from January 2000 to December 2024. Studies assessing IHC markers in histologically verified benign and malignant mesenchymal tumors were incorporated. Pooled sensitivity, specificity, diagnostic odds ratio (DOR), and summary receiver operating characteristic (SROC) curves were computed utilizing a random-effects model.
Results
A total of 42 studies encompassing 3,860 patients were included. Markers including Ki-67, p53, MDM2, CDK4, and HMB45 exhibited significant discriminating efficacy. Ki-67 demonstrated the best pooled sensitivity (0.84; 95% CI: 0.79–0.88), whilst MDM2/CDK4 co-expression displayed the highest pooled specificity (0.91; 95% CI: 0.87–0.94). Substantial heterogeneity was noted among studies, primarily due to tumor subtype and variability in cutoff values.
Conclusion
Immunohistochemical markers substantially assist in distinguishing benign from malignant mesenchymal tumors. A panel-based methodology, as opposed to dependence on a solitary marker, yields enhanced diagnostic precision.
Zitieren
APA
Tripathi, V., Nandi, G., & Gupta, H. (2026). Meta-Analysis of Immunohistochemical Markers for Differentiating Benign and Malignant Mesenchymal Tumors. International Journal of Current Pharmaceutical Review and Research, 18(01). https://doi.org/10.25258/ijcpr.18.1.233
Vancouver
Tripathi V, Nandi G, Gupta H. Meta-Analysis of Immunohistochemical Markers for Differentiating Benign and Malignant Mesenchymal Tumors. International Journal of Current Pharmaceutical Review and Research. 2026;18(01). doi:10.25258/ijcpr.18.1.233
BibTeX
@article{Tripathi2026,
author = {Tripathi, Vivek and Nandi, Gaurav and Gupta, Heeya},
title = {Meta-Analysis of Immunohistochemical Markers for Differentiating Benign and Malignant Mesenchymal Tumors},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {01},
doi = {10.25258/ijcpr.18.1.233}
}
EUVIMED